ORIGINAL ARTICLES

Expression and function of a potential antigen Pb280 as transmission-blocking vaccine in Plasmodium berghei

  • Yu-di WU ,
  • Fei LIU ,
  • Fan YANG ,
  • Ya-ming CAO
Expand
  • Department of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang 110122, China

Received date: 2020-03-04

  Online published: 2021-01-12

Supported by

National Nature Science Foundation of China(81761128017)

Abstract

Objective To investigate the expression and function of a transmission-blocking vaccine candidate Pb280 (PBANKA_041710) in Plasmodium berghei. Methods Homologous sequences of Plasmodium species were downloaded from NCBI and compared using MEGA7. The domains of Pb280 were predicted by SMART. Ten female Kunming (KM) mice aged 6-8 weeks were randomly selected, injected with 1 × 106 P. berghei-infected red blood cells (iRBC) through tail vein. When the parasitemia in the mice reached 3%-5%, orbital blood was obtained and cultured in vitro for isolation of schizonts. The hemagglutinin (HA) tagged plasmid (Pb280HA) and Pb280 knockout plasmid (Pb280KO) were linearized and transfected to mature schizonts, which were then injected in the mice (1 × 107 schizonts/mouse) through tail vein; transgenic parasites in the infected mice was identified by PCR, and underwent monoclonal screening. As a result, one strain of Pb280HA and two strains of Pb280KO (Pb280KO-C1 and Pb280KO-C2) were obtained. The expression of Pb280 in P. berghei was analyzed by Western blotting and indirect immunofluorescence assay (IFA). Another nine female KM mice were randomly divided into 3 groups (n = 3): Pb280KO-C1 group (C1 group), Pb280KO-C2 group (C2 group) and control group. Each mouse was injected with 5 × 106 Pb280KO-C1, Pb280KO-C2 or wild-type (WT) P. berghei through tail vein. From day 3 to day 10 post-infection, mice tail vein blood was sampled for monitoring daily parasitemia by examining blood smears. On day 3 after infection, gametocytemia and female/male gametes ratio were calculated; mice tail vein blood was mixed with ookinete culture medium for 15 min to count the number of exflagellation centers, number of male-female integrating and number of macrogametes followed by further culture for 24 h to count the number of ookinetes. The comparisons of parasitemia, gametocytemia and female/male gamete ratio were performed by Chi-square test, and other data were analyzed with one-way ANOVA. Results Phylogenetic tree constructed by MEGA7 showed that Pb280 was genetically most close to the PY04819 of P. yoelii. SMART prediction showed that Pb280 contained an N-terminal signal peptide, 10 transmembrane domains and 1 growth factor receptor domain. Western blotting demonstrated that Pb280 protein expression occurred in P. berghei, with a relative molecular weight of 280 000. IFA results showed that Pb280 was secreted from cytoplasm to plasma membrane during the development from gametocyte to ookinete. Gene function analysis revealed that on day 3 after infection, the three groups had parasitemia of about 15%, which reached over 60% on day 10 post-infection. The parasitemia rate in the group C1 and the C2 did not differ significantly from that in the control group (P > 0.05). On day 3 post-infection, the gametocytemia rate, gamete sex ratio, number of exflagellation centers per 10 fields of view, number of male-female integrating and number of macrogametes in group C1 were 39.50‰, 1.65, 21.63 ± 4.03, 12.50 ± 8.02, and 930.00 ± 79.20, respetively; those in the group C2 were 34.50‰, 1.71, 18.25 ± 5.85, 13.75 ± 9.54, and 885.00 ± 130.11, respetively; and those in the control group were 41.50‰, 1.74, 21.44 ± 4.73, 15.31 ± 8.06, and 1 018.50 ± 58.69. There were no statistically significant differences among the three groups (P > 0.05). The numbers of ookinetes in the C1, C2 and control groups were 410.00 ± 67.88, 557.50 ± 2.12 and 782.00 ± 41.01, respectively. The numbers of ookinetes in the C1 and C2 groups did not differ significantly, but both were lower than that in the control group (P < 0.05). Conclusion Pb280 is genetically conserved in Plasmodium spp. and expressed in schizont, gametocyte and ookinete stages of P. berghei. Knockout Pb280 may result in the decrease of ookinete formation.

Cite this article

Yu-di WU , Fei LIU , Fan YANG , Ya-ming CAO . Expression and function of a potential antigen Pb280 as transmission-blocking vaccine in Plasmodium berghei[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2020 , 38(6) : 710 -717 . DOI: 10.12140/j.issn.1000-7423.2020.06.006

References

[1] Zhang L, Feng J, Zhang SS, et al. The progress of national malaria elimination and epidemiological characteristics of malaria in China in 2017[J]. Chin J Parasitol Parasit Dis, 2018,36(3):201-209. (in Chinese)
[1] ( 张丽, 丰俊, 张少森, 等. 2017年全国消除疟疾进展及疫情特征分析[J]. 中国寄生虫学与寄生虫病杂志, 2018,36(3):201-209.)
[2] Zhang L, Feng J, Zhang SS, et al. Epidemiological characteristics of malaria and the progress towards its elimination in China in 2018[J]. Chin J Parasitol Parasit Dis, 2019,37(3):241-247. (in Chinese)
[2] ( 张丽, 丰俊, 张少森, 等. 2018年全国疟疾疫情特征及消除工作进展[J]. 中国寄生虫学与寄生虫病杂志, 2019,37(3):241-247.)
[3] Zhang L, Feng J, Xia ZG, et al. Epidemiological characteristics of malaria and progress on its elimination in China in 2019[J]. Chin J Parasitol Parasit Dis, 2020,38(2):133-138. (in Chinese)
[3] ( 张丽, 丰俊, 夏志贵, 等. 2019年全国疟疾疫情特征分析及消除工作进展[J]. 中国寄生虫学与寄生虫病杂志, 2020,38(2):133-138.)
[4] Riley EM, Stewart VA. Immune mechanisms in malaria: new insights in vaccine development[J]. Nat Med, 2013,19(2):168-178.
[5] Ishino T, Tsuboi T. Progress toward a transmission-blocking vaccine against malaria[J]. Lancet Infect Dis, 2018,18(9):927-928.
[6] Williamson KC, Kaslow DC. Strain polymorphism of Plasmodium falciparum transmission-blocking target antigen Pfs230[J]. Mol Biochem Parasitol, 1993,62(1):125-127.
[7] Theisen M, Jore MM, Sauerwein R. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine[J]. Expert Rev Vaccines, 2017,16(4):329-336.
[8] Angrisano F, Sala KA, Da DF, et al. Targeting the conserved fusion loop of HAP2 inhibits the transmission of Plasmodium berghei and falciparum[J]. Cell Rep, 2017,21(10):2868-2878.
[9] Scally SW, McLeod B, Bosch A, et al. Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25[J]. Nat Commun, 2017,8(1):1568.
[10] Kim TS, Kim HH, Moon SU, et al. The role of Pvs28 in sporozoite development in Anopheles sinensis and its longevity in BALB/c mice[J]. Exp Parasitol, 2011,127(2):346-350.
[11] Nikolaeva D, Draper SJ, Biswas S. Toward the development of effective transmission-blocking vaccines for malaria[J]. Expert Rev Vaccines, 2015,14(5):653-680.
[12] Wu YM, Sinden RE, Churcher TS, et al. Development of malaria transmission-blocking vaccines: from concept to product[J]. Adv Parasitol, 2015,89:109-152.
[13] Draper SJ, Sack BK, King CR, et al. Malaria vaccines: Recent advances and new horizons[J]. Cell Host Microbe, 2018,24(1):43-56.
[14] Saxena AK, Wu Y, Garboczi DN. Plasmodium p25 and p28 surface proteins: potential transmission-blocking vaccines[J]. Eukaryot Cell, 2007,6(8):1260-1265.
[15] Liu Y, Tewari R, Ning J, et al. The conserved plant sterility gene HAP2 functions after attachment of fusogenic membranes in Chlamydomonas and Plasmodium gametes[J]. Genes Dev, 2008,22(8):1051-1068.
[16] Miura K, Takashima E, Deng BB, et al. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay[J]. Infect Immun, 2013,81(12):4377-4382.
[17] S Clinical Trials Partnership R. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial[J]. Lancet, 2015,386(9988):31-45.
[18] Tada S, Kitajima T, Ito Y. Design and synjournal of binding growth factors[J]. Int J Mol Sci, 2012,13(5):6053-6072.
Outlines

/

〈 〉